These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: In vitro activity of tigecycline and other tetracyclines against carbapenem-resistant Acinetobacter species: report from a tertiary care centre in Karachi, Pakistan.
    Author: Shakoor S, Khan E, Zafar A, Hasan R.
    Journal: Chemotherapy; 2010; 56(3):184-9. PubMed ID: 20551633.
    Abstract:
    BACKGROUND: The Aga Khan University Hospital is a tertiary care centre in Karachi, Pakistan, where tigecycline has not been used previously. We report findings of a pre-use in vitro study to evaluate sensitivity of nosocomial Acinetobacter spp. Tigecycline minimum inhibitory concentration (MIC) was correlated with that of other tetracyclines to assess their predictive potential. METHODS: Acinetobacter spp. were collected from hospitalized inpatients admitted to Aga Khan University Hospital from April to November 2007. Tigecycline, tetracycline, doxycycline, and minocycline MICs were determined by E-test. RESULTS: One hundred isolates of Acinetobacter spp. were tested. Ninety-eight percent of Acinetobacter spp. were carbapenem-resistant. Tigecycline MIC(50) and MIC(90) were 1.5 and 2.0 microg/ml, respectively. Unavailability of standard breakpoints hindered categorization of these values. Minocycline was highly active, with MIC(90) of 2.0 microg/ml. CONCLUSIONS: Tigecycline breakpoints for Acinetobacter spp. should be established to prevent injudicious use of this antibiotic based on misleading in vitro results. The therapeutic potential of minocycline needs more in-depth study.
    [Abstract] [Full Text] [Related] [New Search]